Nitric oxide donor, V-PROLI/NO, provides protection against arsenical induced toxicity in rat liver cells: Requirement for Cyp1a1

Chemico-Biological Interactions

Volumn 193, Issue 1, 2011, Pages 88-96

  Qu, Wei ^a   Cheng, Lida ^a   Dill, Anna L ^a   Saavedra, Joseph E ^b   Hong, Sam Y ^c   Keefer, Larry K ^c   Waalkes, Michael P ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Arsenic; Cyp1a1; Rat liver cell; V PROLI NO

Indexed keywords

ARSENIC; CYTOCHROME P450; CYTOCHROME P450 1A1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; NITRIC OXIDE; NITRIC OXIDE DONOR; OXYGEN VINYL 1 [2 (CARBOXYLATO)PYRROLIDIN 1 YL]DIAZEN 1 IUM 1,2 DIOLATE; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL METABOLISM; CONTROLLED STUDY; DNA FRAGMENTATION; ENZYME METABOLISM; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LETHALITY; LIVER CELL; LIVER PROTECTION; LIVER TOXICITY; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION;

RATTUS;

EID: 79960015371     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2011.05.005     Document Type: Article

References (40)

1. K. Hede Chinese folk treatment reveals power of arsenic to treat cancer, new studies under way J. Natl. Cancer Inst. 99 2007 667 668
2. S.C. McNeely, A.C. Belshoff, B.F. Taylor, T.W. Fan, M.J. McCabe Jr, A.R. Pinhas, and J.C. States Sensitivity to sodium arsenite in human melanoma cells depends upon susceptibility to arsenite-induced mitotic arrest Toxicol. Appl. Pharmacol. 229 2008 252 261
3. Z.X. Shen, G.Q. Chen, J.H. Ni, X.S. Li, S.M. Xiong, Q.Y. Qiu, J. Zhu, W. Tang, G.L. Sun, K.Q. Yang, Y. Chen, L. Zhou, Z.W. Fang, Y.T. Wang, J. Ma, P. Zhang, T.D. Zhang, S.J. Chen, Z. Chen, and Z.Y. Wang Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients Blood 89 1997 3354 3360
4. Z.Y. Wang, and Z. Chen Acute promyelocytic leukemia: from highly fatal to highly curable Blood 111 2008 2505 2515
5. V. Mathews, S. Desire, B. George, K.M. Lakshmi, J.G. Rao, A. Viswabandya, A. Bajel, V.M. Srivastava, A. Srivastava, and M. Chandy Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity Leukemia 20 2006 881 883
6. J. Liu, and M.P. Waalkes Liver is a target of arsenic carcinogenesis Toxicol. Sci. 105 2008 24 32
7. V. Kozoni, T. Rosenberg, and B. Rigas Development of novel agents based on nitric oxide for the control of colon cancer Acta. Pharmacol. Sin. 28 2007 1429 1433 (Pubitemid 47366693)
8. B. Rigas Novel agents for cancer prevention based on nitric oxide Biochem. Soc. Trans. 35 2007 1364 1368 (Pubitemid 350206501)
9. L.K. Keefer Progress toward clinical application of the nitric oxide-releasing diazeniumdiolates Annu. Rev. Pharmacol. Toxicol. 43 2003 585 607 (Pubitemid 37372654)
10. H. Chakrapani, B.M. Showalter, L. Kong, L.K. Keefer, and J.E. Saavedra V-PROLI/NO, a prodrug of the nitric oxide donor, PROLI/NO Org. Lett. 9 2007 3409 3412
11. A. Anwar-Mohamed, R.H. Elbekai, and A.O. El-Kadi Regulation of CYP1A1 by heavy metals and consequences for drug metabolism Expert. Opin. Drug Metab. Toxicol. 5 2009 501 521
12. V.P. Androutsopoulos, A.M. Tsatsakis, and D.A. Spandidos Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention BMC Cancer 9 2009 187 204
13. W. Qu, J. Liu, A.L. Dill, J.E. Saavedra, L.K. Keefer, and M.P. Waalkes V-PROLI/NO, a nitric oxide donor prodrug, protects liver cells from arsenic-induced toxicity Cancer Sci. 100 2009 382 388
14. Z. Xia, M. Dickens, J. Raingeaud, R.J. Davis, and M.E. Greenberg Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis Science 270 1995 1326 1331
15. J.M. Samet, L.M. Graves, J. Quay, L.A. Dailey, R.B. Devlin, A.J. Ghio, W. Wu, P.A. Bromberg, and W. Reed Activation of MAPKs in human bronchial epithelial cells exposed to metals Am. J. Physiol. 275 1998 L551 558
16. W. Qu, C.D. Bortner, T. Sakurai, M.J. Hobson, and M.P. Waalkes Acquisition of apoptotic resistance in arsenic-induced malignant transformation: role of the JNK signal transduction pathway Carcinogenesis 23 2002 151 159 (Pubitemid 34213564)
17. C.D. Klaassen, J. Liu, and S. Choudhuri Metallothione An intracellular protein to protect against cadmium toxicity Ann. Rev. Pharmacol. Toxicol. 39 1999 267 294
18. H. Kreppel, J.W. Bauman, J. Liu, J.M. McKim Jr., and C.D. Klaassen Induction of metallothionein by arsenicals in mice Fundam. Appl. Toxicol. 20 1993 184 189 (Pubitemid 23162729)
19. G. Jiang, Z. Gong, X.F. Li, W.R. Cullen, and X. C Le Interaction of trivalent arsenicals with metallothionein Chem. Res. Toxicol. 16 2003 873 880 (Pubitemid 36899002)
20. T.T. Ngu, and M.J. Stillman Arsenic binding to human metallothionein J. Am. Chem. Soc. 128 2006 12473 12483 (Pubitemid 44476638)
21. J. Liu, M.L. Cheng, Q. Yang, K. Shan, J. Shen, Y. Zhou, X. Zhang, A. Dill, and M.P. Waalkes Blood metallothionein transcript as a biomarker for metal sensitivity: Low blood metallothionein transcripts in arsenicosis patients from Guizhou, China Environ. Health Perspect. 115 2007 1101 1106 (Pubitemid 47317078)
22. K. Katakai, J. Liu, K. Nakajima, L.K. Keefer, and M.P. Waalkes Nitric oxide induces metallothionein (MT) gene expression apparently by displacing zinc bound to MT Toxicol. Lett. 119 2001 103 108 (Pubitemid 32304371)
23. D.L. Eaton, and T.K. Bammler Concise review of the glutathione S-transferases and their significance to toxicology Toxicol. Sci. 49 1999 156 164 (Pubitemid 29300401)
24. C. Kojima, D.C. Ramirez, E.J. Tokar, S. Himeno, Z. Drobná, M. Stýblo, R.P. Mason, and M.P. Waalkes Requirement of arsenic biomethylation for oxidative DNA damage J. Natl. Cancer Inst. 101 2009 1670 1681
25. D.L. Eaton, and B.F. Toal Evaluation of the Cd/hemoglobin affinity assay for the rapid determination of metallothionein in biological tissues Toxicol. Appl. Pharmacol. 66 1982 134 142 (Pubitemid 13202187)
26. K. Inami, R.W. Nims, A. Srinivasan, L. Michael, M.L. Citro, J.E. Saavedra, I. Arthur, A.I. Cederbaum, and L.K. Keefer Metabolism of a liver-selective nitric oxide-releasing agent, V-PYRRO/NO, by human microsomal cytochromes P450 Nitric Oxide 14 2006 309 315 (Pubitemid 43816314)
27. J.E. Saavedra, T.R. Billiar, D.L. Williams, Y.M. Kim, S.C. Watkins, and L.K. Keefer Targeting nitric oxide (NO) delivery in vivo. Design of a liver-selective NO donor prodrug that blocks tumor necrosis factor-alpha-induced apoptosis and toxicity in the liver J. Med. Chem. 40 1997 1947 1954 (Pubitemid 27265970)
28. W. Qu, J. Liu, R. Fuquay, J.E. Saavedra, L.K. Keefer, and M.P. Waalkes The nitric oxide prodrug, V-PYRRO/NO, mitigates arsenic-induced liver cell toxicity and apoptosis Cancer Lett. 256 2007 238 245 (Pubitemid 47432719)
29. D.J. Waterhouse, J.E. Saavedra, K.M. Davies, M.L. Citro, X. Xu, D.A. Powell, G.J. Grimes, G.K. Potti, and L.K. Keefer Injectable formulation of disodium 1-[2-(carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate (PROLI/NO), an ultrafast nitric oxide donor prodrug J. Pharm. Sci. 95 2006 108 115
30. J.E. Saavedra, G.J. Southan, K.M. Davies, A. Lundell, C. Markou, S.R. Hanson, C. Adrie, W.E. Hurford, W.M. Zapol, and L.K. Keefer Localizing antithrombotic and vasodilatory activity with a novel, ultrafast nitric oxide donor J. Med. Chem. 39 1996 4361 4365 (Pubitemid 26359392)
31. C. Adrie, W.M. Hirani, A. Holzmann, L.K. Keefer, W.M. Zapol, and W.E. Hurford Selective pulmonary vasodilation by intravenous infusion of an ultrashort half-life nucleophile/nitric oxide adduct Anesthesiol. 88 1998 190 195
32. Y. Zhu, and R.B. Silverman Revisiting heme mechanisms. A perspective on the mechanisms of nitric oxide synthase (NOS), Heme oxygenase (HO), and cytochrome P450s (CYP450s) Biochem. 47 2008 2231 2243 (Pubitemid 351304531)
33. D. Meng, X. Wang, Q. Chang, A. Hitron, Z. Zhang, M. Xu, G. Chen, J. Luo, B. Jiang, J. Fang, and X. Shi Arsenic promotes angiogenesis in vitro via a heme oxygenase-1-dependent mechanism Toxicol. Appl. Pharmacol. 244 2010 291 299
34. E.M. Leslie, A. Haimeur, and M.P. Waalkes Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required J. Biol. Chem. 279 2004 32700 32708 (Pubitemid 39014729)
35. W. Qu, K.S. Kasprzak, M. Kadiiska, J. Liu, H. Chen, A. Maciag, R.P. Mason, and M.P. Waalkes Mechanisms of arsenic-induced cross-tolerance to nickel cytotoxicity, genotoxicity, and apoptosis in rat liver epithelial cells Toxicol. Sci. 63 2001 189 195 (Pubitemid 32982792)
36. C. Huang, W.Y. Ma, J. Li, and Z. Dong Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway Cancer Res. 59 1999 3053 3058 (Pubitemid 29316000)
37. H.S. Park, S.H. Huh, M.S. Kim, S.H. Lee, and E.J. Choi Nitric oxide negatively regulates c-Jun N-terminal kinase/stress-activated protein kinase by means of S-nitrosylation Proc. Natl. Acad. Sci. USA. 97 2000 14382 14387 (Pubitemid 32016584)
38. Y.Y. Lo, J.M. Wong, and T.F. Cruz Reactive oxygen species mediate cytokine activation of c-Jun NH2-terminal kinases J. Biol. Chem. 271 1996 15703 15707 (Pubitemid 26225348)
39. I. Falnoga, E. Stibilj, M. Tušek-Žnidarič, Z. Šlejkovec, D. Mazej, R. Jaćimović, and J. Ščančar Effect of arsenic trioxide on metallothionein and its conversion to different arsenic metabolites in hen liver Biol. Trace. Elem. Res. 78 2001 241 254 (Pubitemid 32279650)
40. J. Liu, Y. Liu, R.A. Goyer, W. Achanzar, and M.P. Waalkes Metallothionein-I/II null mice are more sensitive than wild-type mice to the hepatotoxic and nephrotoxic effects of chronic oral or injected inorganic arsenicals Toxicol. Sci. 55 2000 460 467 (Pubitemid 30353255)